Clinical trials: Mood
Major Depressive Disorder, Overweight
Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach
This project aims to evaluate whether a dose-response relationship exists between dose of polyunsaturated fatty acids (PUFA), delivered as eicosapentaenoic acid (EPA), and change in markers of inflammation, and whether these…
- Conditions
- Major Depressive Disorder, Overweight, Inflammation
- Trial name
- NCT02553915
- Testing
- EPA 1 g/day, EPA 2 g/day, EPA 4 g/day
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Clinical Study of Generic and Brand Bupropion in Depression
Determine bioequivalence between branded and generic bupropion extended release (XL) products (and between generic products) at steady state in patients with major depressive disorder.
- Trial name
- BALANCE (NCT02209597)
- Testing
- Bupropion XL 300
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Washington University School of Medicine
Bipolar Disorder, Cocaine Dependence
Valproate Efficacy in Cocaine-Bipolar Comorbidity
This proposal will test the efficacy of a promising pharmacological approach for the treatment of comorbid cocaine dependence and bipolar disorder.
- Trial name
- NCT00240110
- Testing
- Valproate, Lithium Carbonate
- Where
- 2 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- University of Miami
Opioid-use Disorder, Anxiety Disorders
Digital Intervention to Treat Anxiety and Depression Among Persons Receiving Treatment for Opioid Use Disorder
The majority of opioid users meet criteria for anxiety and depressive disorders, but most substance use disorder treatment programs do not offer treatment for co-occurring mental health problems.
- Conditions
- Opioid-use Disorder, Anxiety Disorders, Depressive Disorder
- Trial name
- NCT05047627
- Testing
- Smartphone-Based Digital Intervention
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Trustees of Dartmouth College
Major Depressive Disorder
Safety and Effectiveness of Omega 3-Fatty Acids, EPA Versus DHA, for the Treatment of Major Depression
This study examines the difference in the effectiveness of two natural compounds, eicosapentanoic (EPA) and docosahexanoic (DHA)omega-3 fatty acids, in treating major depressive disorder.
- Trial name
- NCT00361374
- Testing
- eicosapentaenoic acid, docosahexaenoic acid
- Where
- United States
- Volunteers
- 196 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder, Irritability
Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy
To explore the anti-impulsive and anti-aggressive properties of brexpiprazole in a naturalistic setting of depressed patients with irritability.
- Trial name
- NCT01942785
- Testing
- Brexpiprazole
- Where
- 15 sites in United States
- Volunteers
- 55 people
- Sponsor
- H. Lundbeck A/S
Bipolar I Disorder
A Multicenter, Investigative Study of the Safety and Efficacy of Extended Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
To assess the safety and efficacy of long-term administration of aripiprazole by performing extended administration of aripiprazole in combination with mood stabilizer (lithium or valproate) in an unblinded manner to those…
- Trial name
- NCT00606320
- Testing
- Aripiprazole
- Where
- 12 sites in China, Japan and 2 more
- Volunteers
- 59 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Vaccination; Infection
Mood and Influenza Vaccine Response: A Feasibility Trial
This study is a 2-arm, parallel, randomised controlled feasibility trial of a brief video intervention designed to induce positive affect (mood) in older adults in primary care settings prior to the receipt of influenza…
- Trial name
- NCT03144518
- Testing
- Positive Affect Intervention, Neutral Control Intervention, Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)
- Where
- United Kingdom
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Major Depressive Disorder
Neurobiological Bases of Placebo Response in Major Depressive Disorder
We are doing this research study to find out if people who get better while taking a specific kind of antidepressant medication (a selective serotonin reuptake inhibitor, or SSRI) and people who get better while taking placebo…
- Trial name
- NCT01787240
- Testing
- Escitalopram 10mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Massachusetts General Hospital
Bipolar Disorder, Bipolar Depression
Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram
Bipolar depression is one of the least studied depressive illnesses. The standard practice for many doctors is to use antidepressant medicines, but there are few studies on the long-term results of these medicines.
- Trial name
- NCT00562861
- Testing
- citalopram + mood stabilizer
- Where
- United States
- Volunteers
- 119 people
- Sponsor
- Tufts Medical Center
Major Depressive Disorder
Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders…
- Trial name
- NCT04985942
- Testing
- Lumateperone
- Where
- 54 sites in United States, Bulgaria and 4 more
- Volunteers
- 485 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Major Depressive Disorder
Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder
In this study, quetiapine XR or placebo will be administered orally for 6 weeks to major depressive disorder patients with lack of response to existing antidepressants, with the aim of evaluating the efficacy of quetiapine XR and…
- Trial name
- NCT01725282
- Testing
- quetiapine extended release (XR)
- Where
- 3 sites in Japan
- Volunteers
- 172 people
- Sponsor
- Astellas Pharma Inc
Major Depressive Disorder
Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder (MDD)
The purpose of this study is to evaluate the efficacy of vortioxetine (5, 10, and 20 mg) versus placebo during the first 28 weeks of the 32-week double-blind treatment period in the prevention of relapse in participants with MDD…
- Trial name
- NCT02371980
- Testing
- Vortioxetine
- Where
- 79 sites in United States
- Volunteers
- 1,106 people
- Sponsor
- Takeda
Depression, Postpartum Depression
Personalized Integrated Chronotherapy for Perinatal Depression
Perinatal depression and anxiety are common, serious, and frequently overlapping disorders that increase morbidity and mortality in new mothers (including suicide) and result in poor infant/child outcomes.
- Conditions
- Depression, Postpartum Depression, Prenatal Disorder, Circadian Dysregulation
- Trial name
- NCT04364646
- Testing
- Personalized Integrated Chronotherapy
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Rhode Island Hospital
Major Depressive Disorder
Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms
Studies of the neural mechanisms underlying placebo effects in antidepressant clinical trials largely have been limited to demonstrating objective differences in brain activity between responders and non-responders to placebo.
- Trial name
- NCT01919216
- Testing
- Citalopram
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- New York State Psychiatric Institute
Attention, Memory
Polyunsaturated Fatty Acids (PUFA) Status and Cognitive Function in Healthy Young Adults
To date, the relationship between omega-3 polyunsaturated fatty acids (n-3 PUFAs) in cognitively intact individuals has only been examined in a limited number of studies; it is at present unknown whether supplementation with n-3…
- Conditions
- Attention, Memory, Mood, Mental Fatigue
- Trial name
- NCT01075958
- Where
- United Kingdom
- Volunteers
- 283 people, healthy volunteers welcome
- Sponsor
- Northumbria University
Depression
Imaging Biomarkers for TMS Treatment of Depression
The purpose of this research is to learn more about how rTMS works to reduce the symptoms of depression. This information can be used to improve the effectiveness of the treatment.
- Trial name
- NCT01900314
- Testing
- repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan
Bipolar Disorder
Project CARE: An Integrated Treatment Adherence Program for Bipolar Disorder at the Time of Prison Release - Open Trial
The aim of this program of research is to develop and pilot the CARE (Community treatment Adherence at Re-Entry) program, an adjunctive intervention for incarcerated individuals with bipolar disorder (BD) transitioning from…
- Trial name
- NCT03825640
- Testing
- CARE
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Brown University
Migraine, Major Depressive Disorder
A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder
The primary objective is to evaluate the efficacy of monthly 225 mg sc fremanezumab in adult participants with migraine and major depressive disorder (MDD) The secondary objectives are to evaluate the efficacy of monthly 225 mg…
- Trial name
- NCT04041284
- Testing
- Fremanezumab
- Where
- 64 sites in United States, Czechia and 11 more
- Volunteers
- 353 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Major Depressive Disorder
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
This study will evaluate the efficacy of ALKS 5461 when administered daily for 4 weeks to adults with Major Depressive Disorder (MDD) and inadequate response to antidepressant therapy.
- Trial name
- NCT01500200
- Testing
- ALKS 5461
- Where
- 27 sites in United States
- Volunteers
- 142 people
- Sponsor
- Alkermes, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.